Weight loss showdown: GLP-1 drugs vs. surgery for pelvic floor health

NCT ID NCT07175805

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study will follow 200 women who are either taking GLP-1 weight loss drugs or undergoing bariatric surgery. Researchers want to see how these treatments change pelvic floor symptoms like incontinence and prolapse. Participants do not need to have any pelvic floor symptoms to join. The goal is to help doctors recommend the best weight loss option for women with these issues.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GLP-1 receptor agonist (e.g., semaglutide) or bariatric surgery
What this could lead to
If successful, this could help doctors choose the best weight loss treatment for women with pelvic floor issues.
What could go wrong
This is an observational study, not a treatment trial. It will only measure symptoms, not prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BARIATRIC SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fecal Incontinence female stress incontinence Lower Urinary Tract Symptoms overactive bladder pelvic organ prolapse Urinary Incontinence, Stress Urinary Incontinence, Urge Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hartford Hospital

    Hartford, Connecticut, 06106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.